

Cancel Claims 1-22, without prejudice.

Add new Claims 23-46, as follows:

~~23.~~ (new) A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of one or more anti-C3b(i) antibodies.

24. (new) A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount one or more nucleic acid sequences encoding one or more anti-C3b(i) antibodies.

AK  
~~25.~~ (new) A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount of one or more anti-C3b(i) antibodies and one or more antibodies immunospecific for a cancer cell antigen.

~~26.~~ (new) A method for treating or preventing cancer in an animal, said method comprising administering to the animal a therapeutically or prophylactically effective amount one or more nucleic acid sequences encoding one or more anti-C3b(i) antibodies and one or more nucleic acid sequences encoding one or more antibodies immunospecific for a cancer cell antigen.

Sub C / 27. (new) The method of Claim 23, 24, 25 or 26, wherein at least one of the anti-C3b(i) antibodies is immunospecific specific for C3b(i) linked to IgM or IgG bound to cancer cells.

28. (new) The method of Claim 23, 24, 25 or 26, wherein at least one of the anti-C3b(i) antibodies is immunospecific for C3b(i) linked to proteins or lipids on cancer cells.

29. (new) The method of Claim 23, 24, 25 or 26, wherein at least one of the anti-C3b(i) antibodies is a bispecific antibody which is immunospecific for C3b(i) and an effector cell receptor or antigen.

30. (new) The method of Claim 29 in which the effector cell is a lymphocyte, monocyte, macrophage, dendritic cell, neutrophil, natural killer cell, or erythrocyte.

31. (new) The method of Claim 30 in which the effector cell is an erythrocyte.

32. (new) The method of Claim 29 in which the antigen is CR1, CR2, CR3, CR4, CD16, CD32, CD64, or CD89.

33. (new) The method of Claim 23, 24, 25 or 26, wherein at least one of the anti-C3b(i) antibodies is a monoclonal antibody.

34. (new) The method of Claim 33 in which the monoclonal antibody is a human or humanized monoclonal antibody.

35. (new) The method of Claim 23, 24, 25 or 26 further comprising administering to the animal IgG enriched plasma.

36. (new) The method of Claim 23, 24, 25 or 26 further comprising administering to the animal IgM enriched plasma.

37. (new) The method Claim 23, 24, 25 or 26 further comprising administering to the animal one or more complement components.

38. (new) The method of Claim 24 or 26 further comprising administering to the animal one or more nucleic acid sequences encoding one or more complement components.

39. (new) The method of Claim 23 or 25 in which at least one of the anti-C3b(i) antibodies is conjugated to a therapeutic agent.

40. (new) The method of Claim 35 further comprising administering to the animal one or more complement components.